Quick-Med Technologies Announces First Commercial
Sales of NIMBUS® Wound Care Products
New Quick-Med Wound Care Technology
Now Available to $14 Billion Wound Care Market
Gainesville, Florida – June 25, 2009 – Quick-Med Technologies, Inc. (OTCBB:
QMDT) announced today that Derma Sciences (OTCBB: DSCI) has begun selling and
shipping BIOGUARD™ barrier dressings to customers. BIOGUARD is the first wound
dressing to utilize Quick-Med’s proprietary non-leaching NIMBUS® technology.
NIMBUS represents a next generation in advanced wound care and establishes precedent
for a multitude of products with this combination of safe and effective properties.
Quick-Med’s unique NIMBUS technology will offer surgeons, wound care clinicians,
infection control experts and primary care doctors an important new weapon against the
transmission of such virulent bacteria as Methicillin-resistant Staphylococcus aureus
(MRSA). NIMBUS received clearance by the U.S. Food and Drug Administration in late
February, 2009. It is the first non-leaching antimicrobial available in a wound dressing.
NIMBUS is a platform technology that employs a large polyquaternary biocide which is
irreversibly bonded to any of several materials such as cotton, rayon and polyurethane for
use in wound care products. NIMBUS, unlike other antimicrobial agents that require
release into the wound, does not interfere with wound healing and is not susceptible to
originating bacterial resistance.
Derma Sciences separately reported that they have been awarded reimbursement codes
for these novel dressings, allowing the products to be reimbursed by Medicare. Ed Quilty,
CEO of Derma Sciences, stated “We expect BIOGUARD™ to quickly become one of our
most successful new brands to enter into the $14 Billion dollar global wound care
market.”
“It’s exciting that this unique technology is now available to assist healthcare
professionals in their efforts to reduce bacterial infections,” said J. Ladd Greeno, CEO of
Quick-Med. “Derma Sciences has done an excellent job in a short time of scaling up marketing, manufacturing and packaging to stimulate and satisfy surging demand for
BIOGUARD,” he added.
NIMBUS is unique in that it is a sterile bacterial barrier that prohibits the transfer of
microorganisms into the wound because the microbicidal agent is permanently bound to
the dressing. NIMBUS is non-toxic, long-lasting and not blocked by organics such as
blood, urine and perspiration. Product labeling has been allowed that indicates various
organisms such as MRSA, VRE, Pseudomonas aeruginosa and Escherichia coli are
killed at levels exceeding 99.999%.
“Traditional wound dressings absorb fluid from the wound and act as a great incubator
for bacteria that are shed back into the wound,” says Gregory Schultz, Professor, Institute
for Wound Research at the University of Florida and Past President of the Wound
Healing Society. “This [NIMBUS] is the first bound, antimicrobial material – rather than
delivering an antimicrobial into the wound, it creates a barrier that won’t allow bacteria
to penetrate the dressing or grow in the wound fluid.”
NIMBUS poses no danger of bacteria developing resistance, or of releasing toxic
material into the wound and impeding the wound healing process. It is a novel
antimicrobial technology: bonded and effective even in high concentrations of body
fluids.
|
